Doctors in Omaha who helped to treat a surgeon who had contracted Ebola in Sierra Leone said at a news conference Monday that the virus had progressed too far for him to be saved.
Nebraska Medical Center called its treatment of Dr. Martin Salia a “heroic effort.” Salia arrived critically ill on Saturday and was given the experimental drug ZMapp as well as a transfusion of blood from someone who had survived the disease. The hospital, which had previously treated two other cases successfully, did not disclose the donor.
“Even though this was the best possible place for a patient, at the very advanced stages, even the most modern techniques that we have at our disposal are not enough to treat these patients,” said a hospital representative involved in Salia’s care during the news conference.
Salia was said to have no kidney function, working extremely hard to breathe and was unresponsive. The hospital placed Salia on dialysis but he eventually went into complete respiratory failure. He had severely low blood pressure and progressed to cardiac arrest. He died around 4 a.m. on Monday.
“It was an absolute honor to care for Dr. Salia,” said one of the nurses involved in his care.
The White House issued a statement after news of Salia’s death became public: “Dr. Salia’s passing is another reminder of the human toll of this disease and of the continued imperative to tackle this epidemic on the frontlines, where Dr. Salia was engaged in his calling.”
More than 5,000 people have died in the Ebola outbreak, the World Health Organization reports, including at least 324 health care workers.
- Amanda Gorman on the Greatest Lesson She’s Learned This Year
- What Actually Worries U.S. Doctors About Omicron
- Reuniting Families Separated Under Trump Is Expensive. Should the U.S. Government Pay?
- The 10 Best Movies of 2021
- America's Foster Care System Is a Dangerous Place for Trans Teens. Now They're Fighting for Change
- Stressed About Going Back to the Office? Here Are 8 Ways to Make It Easier
- What to Know About Digital World, the Company Funding Trump's New Social Media Platform 'TRUTH Social'